Thalidomide

Generic Name: Thalidomide

Brand Names: Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₀N_₂O_₄

CAS Number: 50-35-1

Unique Ingredient Identifier: 4Z8R6ORS6L

Background: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.

Indication: Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

Associated Conditions: Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma

Associated Therapies: -

Clinical Trials

Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients

Not Applicable

Conditions: Crohn Disease

Interventions: Drug: Thalidomide
Drug: infliximab, azathioprine
Other: enteral nutrition

First Posted Date: 2016-12-20

Last Posted Date: 2016-12-20

Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Target Recruit Count: 90

Registration Number: NCT02998827

The Effective and Safety of Thalidomide in NTDT

Phase 2

Conditions: Thalassemia

Interventions: Drug: Thalidomide

First Posted Date: 2016-12-16

Last Posted Date: 2017-03-22

Lead Sponsor: Xiao-Lin Yin

Target Recruit Count: 30

Registration Number: NCT02995707

Locations: 🇨🇳
NO.3 Hospital of the Chinese People's Liberation Army, Nanjing, Guangxi, China

Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis

Phase 2

Conditions: Cardiac Amyloidosis

Interventions: Drug: Thalidomide
Drug: Dexamethasone

First Posted Date: 2016-11-17

Last Posted Date: 2017-10-26

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 30

Registration Number: NCT02966522

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide

Early Phase 1

Conditions: Crohn Disease

Interventions: Drug: placebo(for thalidomide)
Drug: Thalidomide

First Posted Date: 2016-11-06

Last Posted Date: 2016-11-06

Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Target Recruit Count: 72

Registration Number: NCT02956538

Locations: 🇨🇳
Department of Gastroenterology, Guangzhou, Guangdong, China

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Thalidomide
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-29

Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Target Recruit Count: 124

Registration Number: NCT02891811

Locations: 🇦🇹
Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik, Kufstein, Austria
🇦🇹
Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2, Mitterweng, Austria
🇦🇹
Ordensklinikum Linz - Elisabethinen, I. Interne Abt. Haemato-Onkologie, Linz, Austria

and more 18 locations

Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors

Phase 1

Conditions: Advanced Solid Tumor
Advanced/Metastatic Colorectal Cancer

Interventions: Drug: Simmitecan
Drug: 5-fluorouracil and Leucovorin Calcium
Drug: Thalidomide

First Posted Date: 2016-08-17

Last Posted Date: 2017-07-14

Lead Sponsor: Haihe Biopharma Co., Ltd.

Target Recruit Count: 243

Registration Number: NCT02870036

Locations: 🇨🇳
Beijing Cancer Hospital, Beijin, Beijing, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, China

and more 6 locations